Back to News
Market Impact: 0.12

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Source: PR Newswire

Legal & LitigationCompany FundamentalsInvestor Sentiment & Positioning

Schall, Brown & Schwartz LLP reminded investors of a pending class action against Capricor Therapeutics (NASDAQ: CAPR) alleging violations of Sections 10(b) and 20(a). The notice does not provide financial results or quantify damages, so likely impact is limited in the near term, but it adds legal overhang and investor caution around CAPR.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly negative

Sentiment Score

-0.15

Ticker Sentiment

CAPR-0.95

More News